Equal-WT
WhaleScore 2.0
?
ECOR1 CAPITAL, LLC
SAN FRANCISCO CA
Investment Advisor
Hedge Fund
Ecor1 Capital is based out of San Francisco. Ecor1 Capital is a hedge fund with 5 clients and discretionary assets under management (AUM) of $5,001,741,440 (Form ADV from 2024-10-18). Their last reported 13F filing for Q1 2025 included $1,686,022,983 in managed 13F securities
and a top 10 holdings concentration of 79.99%. Ecor1 Capital's largest holding is Apellis Pharmaceuticals Inc with shares held of 11,895,808. Whalewisdom has at least 48 13F filings, 19 13D filings, 289 13G filings, and 50 Form 4 filings
Business Description
EcoR1 Capital, LLC ("EcoR1") is a limited liability company that has been in business since 2012. EcoR1's manager, controlling owner, and portfolio manager is Oleg Nodelman. As of December 31, 2024, EcoR1 had total discretionary net assets under management of approximately $2.785 billion.
EcoR1 only manages assets on a discretionary basis. EcoR1 does not currently have any separately-managed account clients and therefore does not have any clients that direct EcoR1 to use a specific broker.
Investment Strategy
EcoR1 invests in securities, primarily equity and equity-related securities, of biotechnology companies globally, both long and short. They may also invest in preferred stocks, convertible securities, warrants, rights, options, swaps, other derivative instruments, bonds, fixed income securities, currencies, and money market instruments. EcoR1 engages in margin trading, hedging, and other investment strategies. The specific strategies differ between the Capital Funds, Venture Funds, and SPVs, as detailed in Item 4 and each fund's offering materials.
EcoR1's investment strategies are general and not exhaustive, with no limits on security types, position types, investment concentration, or leverage. They may use any trading or investment techniques, even if not initially contemplated. The firm may pursue any objectives or techniques it deems appropriate and in clients' interest, depending on market conditions.
Owners
- OLEG & HEATHER NODELMAN JOINT REVOCABLE TRUST - MEMBER
- NODELMAN, OLEG, NMN - MANAGER
- MARRIOTT, SARAH, CHRISTINE - MEMBER, CCO, COO
- PERLEN, SCOTT, ERIC - CFO Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| ANAB AnaptysBio Inc | 4.75% |
| ZYME Zymeworks Inc | 3.87% |
| SRPT Sarepta Therapeutics | 1.35% |
| APLS Apellis Pharmaceutic | 1.09% |
| AKRO Akero Therapeutics I | 1.06% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| PFE Pfizer, Inc (CALL) | 5.02% |
| ARVN Arvinas Inc | 4.88% |
| SWTX SpringWorks Therapeu | 2.13% |
| THRD Third Harmonic Bio I | 1.24% |
| NMRA Neumora Therapeutics | 0.83% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| APLS Apellis Pharmaceutic | 15.43% |
| JAZZ Jazz Pharmaceuticals | 12.57% |
| ZYME Zymeworks Inc | 12.19% |
| ANAB AnaptysBio Inc | 8.69% |
| CRNX Crinetics Pharmaceut | 8.53% |
2025-03-31
13F Activity
| Market Value | $1.69b, Prior: $2.65b |
| Inflows (Outflows) as % of Total MV | (-12.7941)% |
| New Purchases | 4 stocks |
| Added To | 11 stocks |
| Sold out of | 17 stocks |
| Reduced holdings in | 6 stocks |
| Top 10 Holdings % | 79.99% |
| Turnover %[1] | 33.33% |
| Turnover Alt %[2] | 6.2% |
| Time Held Top 20 | 7.95 quarters |
| Time Held Top 10 | 6.6 quarters |
| Time Held All | 7.8 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31